At the present time, genetic evaluation guidelines for prostate cancer primarily focus on BRCA1 and BRCA2 testing. The overall risk of prostate cancer has been reported up to 3.8-fold for men who carry BRCA1 mutations and up to 8.6-fold for men who carry BRCA2 mutations.
Experts discuss the complex relationship between androgen signaling and hypoxia-driven signaling pathways in prostate cancer and how to tailor chemotherapy, radiotherapy, and immunotherapy to treat this disease.
Dr. Ashish M. Kamat (pictured) and Dr. Matthew T. Campbell discuss the state of immunotherapeutics and targeted therapy and the potential impact of biomarkers and molecular subtyping in personalizing therapy for urothelial cancer.
Patients with non–clear cell RCC represent a heterogeneous group of distinct disease entities. These patients have historically been underrepresented in clinical trials, and there is a need for further prospective studies exploring current and novel agents in this patient population.